Tranexamic Acid for Reduction of Transfusion in Abdominal Surgery - Trial NCT06414031
Access comprehensive clinical trial information for NCT06414031 through Pure Global AI's free database. This Phase 3 trial is sponsored by Ulrich Ronellenfitsch, MD and is currently Not yet recruiting. The study focuses on Surgical Blood Loss,Transfusion-dependent Anemia,Abdomen Disease. Target enrollment is 850 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Ulrich Ronellenfitsch, MD
Martin-Luther-Universität Halle-Wittenberg
Timeline & Enrollment
Phase 3
Jun 01, 2024
Nov 30, 2025
Primary Outcome
Transfusion necessity
Summary
The goal of this clinical trial is to learn if the administration of tranexamic acid can
 reduce the necessity of blood transfusions in adult patients undergoing major abdominal
 surgery. . It will also inform about safety of tranexamic acid in this setting.
 
 The main question it aims to answer is: Does tranexamic acid lower the probability of
 receiving at least one blood transfusion during or after surgery?
 
 Participants will compare tranexamic acid o a placebo (a look-alike substance that contains
 no drug) to see if tranexamic acid works to reduce the necessity of a blood transfusion.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06414031
Non-Device Trial